UnitedHealth (UNH) Shareholders Approve CEO's $60M Stock Award amid Uncertainty
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The pay package includes a $1 million annual salary and a $60 million stock option award, which will vest over three years.
It must be noted that the approval came despite a warning from investor advisory group Institutional Shareholder Services (ISS) last month. ISS advised to vote against the pay package, saying it raises concerns because the bonus is not tied to company goals.
Leadership Change at UnitedHealth
In a brief background, Hemsley took over from Andrew Witty, who led UNH for four years before stepping down. The company faces several challenges during this change.
In December, Brian Thompson, head of the company's insurance branch, was killed in midtown Manhattan. Adding to the company's woes, shareholders filed a lawsuit last month alleging that UNH hid how Thompson's death hurt its business. The lawsuit claims UnitedHealth misled investors by changing its claims strategy without warning about lower profits.
Further, UNH is reportedly under investigation by the Department of Justice for potential criminal Medicare fraud, according to The Wall Street Journal.
Hemsley Pledges to Rebuild Trust
Speaking at the annual shareholder meeting, Hemsley acknowledged the company's recent missteps, promising to restore investor trust and conduct a review of UnitedHealth's policies.
Hemsley said that UNH underestimated both the volume and the cost of medical care that patients would require. He added that the company is updating its estimates and has adjusted its bids for Medicare Advantage plans.
What Is the Future of UNH Stock?
Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 19 Buys, six Holds, and one Sell assigned in the last three months. At $377.77, the average UnitedHealth stock price target implies a 23.97% upside potential.
See more UNH analyst ratings
Disclaimer & Disclosure Report an Issue
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Source: Sarepta Therapeutics, Inc.
Globe and Mail
41 minutes ago
- Globe and Mail
Amberton University Completes Major Overhaul, Revamping 100% of Courses and Expanding Programs
New initiatives include innovative AI integration, career-focused curriculum, and expanded healthcare and business programs. Garland, Texas--(Newsfile Corp. - July 25, 2025) - Amberton University announced today the completion of a comprehensive overhaul, revamping all courses and significantly expanding its program offerings for the 2025-2026 academic year. To view an enhanced version of this graphic, please visit: This initiative includes innovative AI integration, a highly career-focused curriculum, and expanded healthcare and business programs. "All Amberton courses have been completely updated with modern, real-world skills and AI competencies," stated Dr. Carol A. Palmer, President of Amberton University. Established over 50 years ago, Amberton University is renowned for its affordable, flexible education tailored specifically for working adults. Major Curriculum Overhaul Amberton has updated every course offered, clearly defining industry-driven skills across key programs such as project management, finance, clinical mental health counseling, and school counseling. This strategic initiative enhances graduates' career readiness and significantly boosts their practical value to employers. A Leader in AI Literacy Amberton is among the first fully AI-literate campuses nationwide, integrating AI competencies into every course. Business courses emphasize AI-driven strategies, Finance courses incorporate AI-based financial analysis, and Counseling courses explore AI-assisted therapeutic interventions. The newly launched Master of Science in Applied Artificial Intelligence program emphasizes responsible and strategic AI implementation. Students gain practical, hands-on learning experiences through an interactive AI Testing Environment, building tangible portfolios that demonstrate their AI proficiency. New Degree Programs and Certificates Amberton has introduced four critical new degree programs aligned with market demands: Master of Science in Applied Artificial Intelligence Master of Healthcare Administration (MHA) - This program is designed for individuals aiming to excel in executive and managerial positions within the healthcare sector. MBA in Finance - Focusing on fintech, cryptocurrency, blockchain, and advanced financial analytics. Master of Science in Training & Development - Addressing the increasing demand for workforce training and digital education. Additionally, nine practical certificate programs have been added as pathways toward full degrees, tailored to immediate industry needs. Commitment to Affordable, Quality Education Amberton maintains its position as one of the most affordable institutions nationwide, clearly outlining a transparent tuition model on its website. By avoiding unnecessary infrastructure costs, Amberton provides affordability without compromising educational quality. Faculty Voices and Industry Expertise Amberton faculty incorporate professional expertise directly into their instruction: Dr. Don Hebbard, Counseling: "Our students graduate ready to immediately make a difference, both professionally and personally." Dr. Deborah Hill, Human Development: "We're providing education that's immediately relevant to the workforce, not just theory." Dr. Ron Norris, Healthcare Administration: "Amberton's new healthcare program fills a critical need for qualified leaders in a rapidly growing healthcare sector." Dr. John Sinclair, AI Program Coordinator: "Amberton's AI curriculum uniquely positions graduates to become ethical, innovative leaders in AI implementation." Dr. Ken Johnson, Clinical Mental Health: "We remain highly responsive to student needs, continuously improving our counseling program to reflect current mental health practices." Student Success and Outcomes "This major overhaul is not just an update. It's Amberton's commitment to preparing our students for success in a rapidly changing world," stated Dr. Palmer. "Our students deserve an education that makes practical sense, and that's exactly what Amberton delivers." Interested students and professionals can apply easily and at no cost via the university's streamlined admission portal.
Globe and Mail
41 minutes ago
- Globe and Mail
5 Dividend Stocks to Hold for the Next 20 Years
These five dividend giants (plus two honorable mentions) aren't just income plays -- they're global titans with decades of growth, consistent payouts, and bulletproof brands. From Coca-Cola 's (NYSE: KO) unmatched dividend legacy to Linde 's (NASDAQ: LIN) green energy future, these stocks are built to weather any storm and compound wealth for decades. *Stock prices used were the market prices of July 23, 2025. The video was published on July 25, 2025. Should you invest $1,000 in Coca-Cola right now? Before you buy stock in Coca-Cola, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Coca-Cola wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of July 21, 2025 Bank of America is an advertising partner of Motley Fool Money. Rick Orford has positions in Eli Lilly. The Motley Fool has positions in and recommends Abbott Laboratories and Walmart. The Motley Fool recommends AstraZeneca Plc and Linde. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
